Received Nov 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
An adult male patient received a pediatric dose of Engerix-B; An adult male patient received a pediatric dose of Engerix-B; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 45-year-old male patient who received HBV (Engerix B pediatric) for prophylaxis. On 25-SEP-2025, the patient received Engerix B pediatric. On 25-SEP-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: An adult male patient received a pediatric dose of Engerix-B) and underdose (Verbatim: An adult male patient received a pediatric dose of Engerix-B). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 28-Oct-2025 The reporter reported that they administered a pediatric dose of Engerix-B to an adult male patient and asked that did they need to revaccinate and did they had to continue with the adult series. The batch number was not provided upon follow up with the reporter.